OraSure Technologies, Inc. (OSUR) Short Interest Update

OraSure Technologies, Inc. (NASDAQ:OSUR) saw a large decline in short interest in November. As of November 15th, there was short interest totalling 1,638,690 shares, a decline of 71.2% from the October 31st total of 5,687,629 shares. Approximately 2.8% of the company’s stock are sold short. Based on an average trading volume of 1,870,558 shares, the short-interest ratio is currently 0.9 days.

A number of brokerages have recently issued reports on OSUR. Zacks Investment Research downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. Jefferies Group reissued a “buy” rating and issued a $20.00 price objective on shares of OraSure Technologies in a research note on Tuesday, September 12th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 price target on shares of OraSure Technologies in a research note on Tuesday, September 19th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $18.21.

In related news, CEO Douglas A. Michels sold 25,000 shares of the company’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $22.55, for a total value of $563,750.00. Following the completion of the sale, the chief executive officer now owns 743,058 shares in the company, valued at approximately $16,755,957.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Mara G. Aspinall purchased 5,000 shares of OraSure Technologies stock in a transaction that occurred on Tuesday, November 7th. The stock was acquired at an average price of $14.23 per share, with a total value of $71,150.00. Following the transaction, the director now owns 5,000 shares in the company, valued at $71,150. The disclosure for this purchase can be found here. Insiders own 6.40% of the company’s stock.

Institutional investors have recently modified their holdings of the business. State Street Corp grew its stake in shares of OraSure Technologies by 6.9% in the 2nd quarter. State Street Corp now owns 1,639,620 shares of the medical instruments supplier’s stock valued at $28,305,000 after buying an additional 106,326 shares in the last quarter. Federated Investors Inc. PA lifted its holdings in OraSure Technologies by 505.6% in the 2nd quarter. Federated Investors Inc. PA now owns 312,595 shares of the medical instruments supplier’s stock worth $5,395,000 after purchasing an additional 260,977 shares during the last quarter. USA Financial Portformulas Corp lifted its holdings in OraSure Technologies by 31.0% in the 2nd quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock worth $978,000 after purchasing an additional 13,421 shares during the last quarter. Chicago Equity Partners LLC lifted its holdings in OraSure Technologies by 38.3% in the 2nd quarter. Chicago Equity Partners LLC now owns 78,430 shares of the medical instruments supplier’s stock worth $1,354,000 after purchasing an additional 21,730 shares during the last quarter. Finally, 361 Capital LLC lifted its holdings in OraSure Technologies by 59.9% in the 2nd quarter. 361 Capital LLC now owns 26,974 shares of the medical instruments supplier’s stock worth $466,000 after purchasing an additional 10,107 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Shares of OraSure Technologies (NASDAQ OSUR) opened at $17.34 on Tuesday. The firm has a market cap of $1,053.46, a P/E ratio of 33.40, a PEG ratio of 3.34 and a beta of 1.28. OraSure Technologies has a 1 year low of $8.39 and a 1 year high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The firm had revenue of $42.30 million during the quarter, compared to the consensus estimate of $40.87 million. During the same quarter in the previous year, the company posted $0.11 earnings per share. The firm’s revenue was up 31.0% on a year-over-year basis. research analysts anticipate that OraSure Technologies will post 0.42 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “OraSure Technologies, Inc. (OSUR) Short Interest Update” was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://weekherald.com/2017/12/12/orasure-technologies-inc-osur-short-interest-down-71-2-in-november.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply